Xenon Pharmaceuticals (XENE) Other Non-Current Assets (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Other Non-Current Assets of $8.3 million for Q1 2026, up 3.13% year-over-year from $8.1 million in Q1 2025, and up 16.14% quarter-over-quarter from $7.2 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Other Non-Current Assets for 10 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 3.13% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (up 3.13% YoY), while the FY2025 annual figure was $7.2 million, down 4.6% from the prior year.
- Other Non-Current Assets climbed to $8.3 million in Q1 2026 per XENE's latest filing, from $7.2 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $9.2 million in Q2 2025 and bottomed at $7.1 million in Q3 2025.
- Historically, Other Non-Current Assets has averaged $7.7 million across 5 years, with a median of $7.5 million in 2024.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets retreated 8.2% — and 2025, when it advanced 23.89%.
- Xenon Pharmaceuticals' Other Non-Current Assets stood at $7.8 million in 2022, then fell by 4.58% to $7.4 million in 2023, then rose by 1.35% to $7.5 million in 2024, then retreated by 4.6% to $7.2 million in 2025, then grew by 16.14% to $8.3 million in 2026.
- Business Quant data shows XENE's Other Non-Current Assets at $8.3 million in Q1 2026, $7.2 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 7.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.97 Mn |
| Mar 31, 2026 | 8.31 Mn |
| Dec 31, 2025 | 7.15 Mn |
| Sep 30, 2025 | 7.11 Mn |
| Jun 30, 2025 | 9.19 Mn |
| Mar 31, 2025 | 8.05 Mn |
| Dec 31, 2024 | 7.50 Mn |
| Sep 30, 2024 | 7.47 Mn |
| Jun 30, 2024 | 7.42 Mn |
| Mar 31, 2024 | 7.31 Mn |
| Dec 31, 2023 | 7.40 Mn |
| Sep 30, 2023 | 7.34 Mn |
| Jun 30, 2023 | 7.88 Mn |
| Mar 31, 2023 | 7.96 Mn |
| Dec 31, 2022 | 7.75 Mn |
| Dec 31, 2017 | 230,000.00 |
| Sep 30, 2017 | 218,000.00 |
| Jun 30, 2017 | 285,000.00 |
| Mar 31, 2017 | 269,000.00 |
| Dec 31, 2016 | 408,000.00 |